Skip to main content

Table 1 Demographics for individuals with ME/CFS taking aripiprazole (Abilify)

From: Off label use of Aripiprazole shows promise as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a retrospective study of 101 patients treated with a low dose of Aripiprazole

Demographics Responders Non-responders Total
Individuals with ME/CFS, n (%) 75 (74.3%) 26 (25.8%) 101 (100%)
Mean age, years (range) 48.9 (18–76) 52.2 (28–84) 49.7 (18–84)
Duration of illness, years (range) 12.6 (2–54) 15.8 (1–44) 13.4 (1–54)
Female, n (%) 52 (69.4%) 16 (61.5%) 68 (67%)
Male, n (%) 23 (30.6%) 10 (38.5%) 33 (33%)
Aripiprazole dose, mg (range) 1.2 (0.25–2.0) 0.7 (0–2.0) 1.1 (0–2.0)
Duration of treatment, average months (range) 8.0 (0–17) 7.1 (0–13) 7.8 (0–17)
Concurrent antidepressant use 46/75 (61.3%)* 11/26 (42.3%)* 57/101 (56.4%)
  1. *p = 0.145